Page last updated: 2024-12-10

eprosartan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eprosartan: angiotensin II receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281037
CHEMBL ID813
CHEBI ID4814
CHEBI ID94094
SCHEMBL ID4025
MeSH IDM0187027

Synonyms (78)

Synonym
BIDD:GT0030
STK618317
4-({2-butyl-5-[(1e)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
AKOS005552473
eprozar
gtpl588
sk&f-108566
teveten
4-({2-butyl-5-[(1e)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
D04040
eprosartan (usan/inn)
C07467
eprosartan
133040-01-4
DB00876
(e)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1h-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
(e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
(e)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
NCGC00164557-01
2-thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
sk&f 108566
CHEBI:4814 ,
HMS2089O10
sk-108566
CHEMBL813 ,
L000248
bdbm50011977
4-[[2-butyl-5-[(e)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid
eprosartan [usan:inn:ban]
hsdb 7521
unii-2kh13z0s0y
2kh13z0s0y ,
BCP9000656
BCPP000239
eprosartan [inn]
eprosartan [hsdb]
eprosartan [mi]
2-thiophenepropanoic acid, .alpha.-((2-butyl-1-((4-carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)-
(e)-2-butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic acid
eprosartan [usan]
eprosartan [vandf]
eprosartan [who-dd]
[3h]-eprosartan
[3h]eprosartan
gtpl3940
[3h]sk&f 108566
BRD-K67977190-066-01-5
SCHEMBL4025
AB01275448-01
(e)-alpha-[[2-butyl-1-[(4carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-2-thiophene propanoic acid
(e)-alpha-[[2-butyl-1-[(4-carboxyphenyl)-methyl]-1h-imidazol-5-yl]methylene]-2-thiophene propanoic acid
OROAFUQRIXKEMV-LDADJPATSA-N
(e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1h-imidazol-1-yl)methyl)benzoic acid
4-({2-butyl-5-[(1e)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
AB01275448_02
(e)-4-((2-butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-enyl)-1h-imidazol-1-yl)methyl)benzoic acid
DTXSID0022989
sr-05000001450
CHEBI:94094
SR-05000001450-1
J-006289
NCGC00164557-06
(e)-3-[2-butyl-1-[(4-carboxyphenyl)methyl]imidazol-5-yl]-2-(2-thienylmethyl)-2-propenoic acid
4-[[2-butyl-5-(2-carboxy-3-thiophen-2-ylprop-1-enyl)-1-imidazolyl]methyl]benzoic acid
teveten; sk&f108566
BCP02353
Q784717
NCGC00164557-13
4-[[2-butyl-5-[(e)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid
NCGC00164557-11
(alphae)-alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-2-thiophenepropanoic acid
skb 108566
HY-117743
BS-20679
4-({2-butyl-5-[(1e)-2-carboxy-2-[(thiophen-2-yl)methyl]eth-1-en-1-yl]-1h-imidazol-1-yl}methyl)benzoic acid
EN300-7397751
CS-0067582
2-thiophenepropanoic acid, alpha-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazol-5-yl]methylene]-, (alphae)-

Research Excerpts

Overview

Eprosartan is an angiotensin II receptor antagonist used in the treatment of hypertension and heart failure. It is a non-biphenyl, non-tetrazole competitive blocker.

ExcerptReferenceRelevance
"Eprosartan mesylate is a poorly water-soluble drug. "( The preparation and physicochemical characterization of eprosartan mesylate-laden polymeric ternary solid dispersions for enhanced solubility and dissolution rate of the drug.
Hussain, T; Jamshaid, M; Mahmood, T; Shahzad, Y; Yousaf, AM; Zulfiqar, S,
)
1.82
"Eprosartan is an angiotensin II receptor antagonist used as an antihypertensive. "( Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury.
Dohmen, PM; Konertz, W; Modersohn, D; Patil, NP; Sabashnikov, A; Weymann, A, 2014
)
3.29
"Eprosartan is an angiotensin II receptor antagonist, used in the treatment of hypertension and heart failure in clinical patients. "( OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human.
Huo, X; Liu, K; Liu, Q; Meng, Q; Sun, H; Sun, P; Wang, C; Zhang, A, 2014
)
2.08
"Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles)."( Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Blankestijn, PJ; Rupp, H, 2008
)
1.39
"Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension. "( Eprosartan: a review of its use in hypertension.
Plosker, GL, 2009
)
3.24
"Eprosartan is a non-biphenyl, non-tetrazole competitive blocker that is chemically distinct from other AII receptor blockers, which may account for differences in its pharmacological properties."( Clinical profile of eprosartan.
Bernardino, JI; Bueso, TS; Jiménez, RT; López, MA; Puig, JG, 2002
)
1.36
"Eprosartan is a chemically distinct AII blocker, which displays a dual mode of action whereby it blocks both pre- and postsynaptic AT(1) receptors, potentially benefiting patients with hypertension and renal disease."( Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
Jaeger, B; Pascoe, M; Rayner, B; Verboom, CN,
)
1.09
"Eprosartan seems to be an effective drug to reduce SBP, DBP and pulse pressure with the same effectiveness in diabetics and non diabetic patients."( [Anti-hypertensive effect of eprosartan in diabetic patients].
Alonso, FJ; Blanco, J; Gamero, MJ; Jiménez Pérez, JL; Masot, J; Matilla, C; Nieto, J; Robles, NR; Romero, F; Velasco, J, 2004
)
2.06
"Eprosartan is an effective and well-tolerated antihypertensive therapy for elderly patients with ISH."( Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension.
Arcos, E; de la Sierra, A; Lopez, JS; Munoz, A; Relats, J, 2004
)
2.17
"Eprosartan is an effective, well tolerated antihypertensive drug that reduces pulse pressure. "( The effect of treatment with eprosartan on pulse pressure: factors predicting response.
Arcos, E; de la Sierra, A; López, JS; Muñoz, A; Relats, J, 2004
)
2.06
"Eprosartan is an angiotensin II type 1 receptor antagonist with a unique dual mechanism of action that is approved for the treatment of essential hypertension."( Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline.
Ram, CV; Rudmann, MA, 2007
)
1.34
"Eprosartan is a nonpeptide angiotensin II receptor antagonist which has a high affinity for the AT1 receptor subtype. "( Eprosartan.
Balfour, JA; McClellan, KJ, 1998
)
3.19
"Eprosartan is an angiotensin II receptor antagonist being developed for the treatment of hypertension and heart failure. "( Eprosartan does not affect the pharmacodynamics of warfarin.
Boike, S; Forrest, A; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Zariffa, N, 1998
)
3.19
"Eprosartan is a new, structurally distinct, nonbiphenyl, nontetrazole, nonpeptide, orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor. "( Clinical efficacy of eprosartan.
Weber, M, 1999
)
2.07
"Eprosartan is a potent (1.4 nmol/l) AT1 receptor antagonist that inhibits angiotensin-II-induced vascular contraction in a competitive manner."( Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks, DP; Ruffolo, RR, 1999
)
1.02
"Eprosartan is a potent (1.4 nmol/L) AT1 receptor antagonist that competitively blocks angiotensin II-induced vascular contraction."( Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
Brooks, DP; Ohlstein, EH; Ruffolo, RR, 1999
)
1.37
"Eprosartan is a potent and selective angiotensin II subtype 1 receptor antagonist. "( Eprosartan: a review of its use in the management of hypertension.
Foster, RH; Plosker, GL, 2000
)
3.19
"Eprosartan is a selective angiotensin II type I receptor antagonist approved for the treatment of hypertension. "( Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone, FC; Brooks, DP; Campbell, WG; Chandra, S; Coatney, RW; Contino, LC; Nelson, AH; Ohlstein, EH; Sarkar, SK; Willette, RN, 2001
)
3.2
"Eprosartan is a structurally unique ARB."( Issues in hypertension: drug tolerability and special populations.
Gavras, HP, 2001
)
1.03
"Eprosartan is a recent entry into this class."( Pharmacology and clinical efficacy of angiotensin receptor blockers.
Sica, DA, 2001
)
1.03
"Eprosartan is a new nonphenyl angiotensin II receptor blocker, which has been approved for the treatment of hypertension. "( Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.
Anwar, YA; Mansoor, GA; Sica, DA; White, WB, 2001
)
2
"Eprosartan is a competitive angiotensin-II receptor antagonist with a high affinity for the angiotensin-II subtype 1 receptor. "( Eprosartan: an angiotensin-II receptor antagonist for the management of hypertension.
Cheng-Lai, A,
)
3.02

Effects

Eprosartan has a side-effect profile that is similar to placebo and to other AII receptor blockers, but is better than that of enalapril because it lacks the propensity to cause dry cough. The drug has a low potential for serious adverse events and has not been associated with clinically significant drug interactions.

Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile. It has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies.

ExcerptReferenceRelevance
"Eprosartan has a neutral effect on metabolic parameters, such as serum lipid levels and glucose homeostasis, and a low propensity for pharmacokinetic drug interactions."( Eprosartan: a review of its use in hypertension.
Plosker, GL, 2009
)
2.52
"Eprosartan has a side-effect profile that is similar to placebo and to other AII receptor blockers, but is better than that of enalapril because it lacks the propensity to cause dry cough."( Clinical profile of eprosartan.
Bernardino, JI; Bueso, TS; Jiménez, RT; López, MA; Puig, JG, 2002
)
1.36
"Eprosartan has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies."( Eprosartan: a review of its use in the management of hypertension.
Robins, GW; Scott, LJ, 2005
)
2.49
"Eprosartan has a low potential for serious adverse events, and the drug has not been associated with clinically significant drug interactions."( Eprosartan: a review of its use in the management of hypertension.
Foster, RH; Plosker, GL, 2000
)
2.47
"Eprosartan has an adequate corrective activity in relation to absolute values of SAP and DAP in different hours. "( [Significance of pharmacological blockade of angiotensin II type I receptors for correction of abnormal 24-hour blood pressure profile depending on its variability in patients with arterial hypertension stage II].
Al'-Iazidi, MA; Barsukov, AV; Konev, AV; Kulikov, AN; Shustov, SB, 2002
)
1.76
"Eprosartan has a neutral effect on metabolic parameters, such as serum lipid levels and glucose homeostasis, and a low propensity for pharmacokinetic drug interactions."( Eprosartan: a review of its use in hypertension.
Plosker, GL, 2009
)
2.52
"Eprosartan has been shown to be well tolerated with a placebo-like adverse-effect profile."( Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Böhm, M; Sachse, A, 2002
)
1.33
"Eprosartan has a side-effect profile that is similar to placebo and to other AII receptor blockers, but is better than that of enalapril because it lacks the propensity to cause dry cough."( Clinical profile of eprosartan.
Bernardino, JI; Bueso, TS; Jiménez, RT; López, MA; Puig, JG, 2002
)
1.36
"Eprosartan has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies."( Eprosartan: a review of its use in the management of hypertension.
Robins, GW; Scott, LJ, 2005
)
2.49
"Eprosartan has shown positive effects on vascular inflammation and resistance to oxidation and/or modification of low-density lipoprotein."( Angiotensin blockade with eprosartan: vascular and functional implications.
Ram, CV, 2007
)
1.36
"Eprosartan also has sympathoinhibitory activity, as demonstrated by an inhibition of the pressor responses induced by activation of sympathetic outflow through spinal cord stimulation in pithed rats."( Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
Brooks, DP; Ohlstein, EH; Ruffolo, RR, 1999
)
1.37
"Eprosartan has a low potential for serious adverse events, and the drug has not been associated with clinically significant drug interactions."( Eprosartan: a review of its use in the management of hypertension.
Foster, RH; Plosker, GL, 2000
)
2.47
"Eprosartan has an adequate corrective activity in relation to absolute values of SAP and DAP in different hours. "( [Significance of pharmacological blockade of angiotensin II type I receptors for correction of abnormal 24-hour blood pressure profile depending on its variability in patients with arterial hypertension stage II].
Al'-Iazidi, MA; Barsukov, AV; Konev, AV; Kulikov, AN; Shustov, SB, 2002
)
1.76

Actions

Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) and markedly increased circulating Ang-II levels. It did not blunt sympathetic activation caused by lower body negative pressure or mental stress.

ExcerptReferenceRelevance
"Eprosartan did not blunt sympathetic activation caused by lower body negative pressure or mental stress."( Elevation of sympathetic activity by eprosartan in young male subjects.
Heusser, K; Raasch, W; Schmieder, RE; Schobel, HP; Vitkovsky, J, 2003
)
1.31
"Eprosartan tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating Ang-II levels (p<0.01). "( AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
Heusser, K; Schmieder, RE; Schobel, HP; Vitkovsky, J, 2003
)
2.1

Treatment

Eprosartan pretreatment could also abolish I/R-induced alterations in the apoptotic parameters. Treatment with e Prostartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated.

ExcerptReferenceRelevance
"Eprosartan pretreatment could also abolish I/R-induced alterations in the apoptotic parameters."( Protective effect of Eprosartan against ischemic acute renal injury: Acting on NF-κB, caspase 3, and Sirtuin 1.
Abdollahpour, A; Ahmadian, E; Bagheri, Y; Firouzfar, A; Khajepour, F; Lotfi, B; Matin, S; Zununi Vahed, S, 2023
)
1.95
"Eprosartan-treated group with 30 mg/kg Eprosartan intraperitoneally 30 min before occlusion of renal pedicles followed by 30 minutes of ischemia and 2 hours of reperfusion."( PROTECTIVE EFFECT OF EPROSARTAN IN RENAL ISCHEMIA REPERFUSION INJURY BY REGULATING OXIDATIVE STRESS, INFLAMMATION, AND APOPTOTIC CASCADES IN A BILATERAL RAT MODEL.
Al-Sultany, HHA; Altimimi, ML; Hadi, NR, 2023
)
1.95
"Eprosartan-treated SP-SFD rats maintained normal weight, and exhibited zero mortality at week 12 and beyond."( Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone, FC; Brooks, DP; Campbell, WG; Chandra, S; Coatney, RW; Contino, LC; Nelson, AH; Ohlstein, EH; Sarkar, SK; Willette, RN, 2001
)
2.47
"Pre-treatment with Eprosartan is associated with a significant improvement in regional cardiac function under ischemic conditions. "( Eprosartan improves cardiac function in swine working heart model of ischemia-reperfusion injury.
Dohmen, PM; Konertz, W; Modersohn, D; Patil, NP; Sabashnikov, A; Weymann, A, 2014
)
2.17
"Treatment with eprosartan was associated with improvements of impaired left ventricular diastolic function, structural and functional state of the heart, venous outflow from cerebral vessels, and restoration of unpaired autoregulation of cerebral blood flow."( [Effect of eprosartan on left ventricular diastolic function and cerebral hemodynamics in patients with hypertension].
Belavina, NI; Griabina, NA; Koren'kov, VV; Markova, LI; Radzevich, AE; Zharova, OIu, 2002
)
1.04
"Treatment with eprosartan in once-daily doses up to 1200 mg alone or in combination with HCTZ was well tolerated, with dizziness and asthenia being the most common side effects."( Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi, CF; Punzi, HA, 2004
)
1.05

Toxicity

The overall incidence of adverse events was comparable to that in the enalapril group. The frequency of adverse event observed with eprosartan was similar to that seen with placebo.

ExcerptReferenceRelevance
" The frequency of adverse events observed with eprosartan was similar to that seen with placebo."( Safety and tolerability of eprosartan.
Gavras, H; Gavras, I, 1999
)
0.86
" Most adverse experiences reported throughout the study were mild or moderate in both treatment groups."( Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras, H; Gavras, I, 1999
)
0.69
" Eprosartan was well tolerated; the overall incidence of adverse events was comparable to that in the enalapril group."( Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Sega, R, 1999
)
1.52
"Control of hypertension is hindered by the incidence of adverse events associated with therapy, which can result in low patient compliance."( Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine, B, 2001
)
1.75
"The ideal antihypertensive drug should be effective in reducing blood pressure, but have a low incidence of adverse effects."( Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Böhm, M; Sachse, A, 2002
)
0.61
" Twenty adverse events, mostly gastrointestinal complaints, were recorded in 12 patients (1."( Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
Alamo, C; López-Muñoz, F; Martín-Agueda, B; Robles, NR, 2005
)
0.62
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

Eprosartan terminal half-life was shorter after i. Serial pharmacokinetic samples were obtained for up to 24 hours following dosing. There were approximately two fold higher AUC and Cmax values for eprosArtan observed in elderly men as compared with young men.

ExcerptReferenceRelevance
" tmax was similar for both regimens."( Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
Boike, SC; Citerone, D; Ilson, B; Jorkasky, DK; Martin, DE; Tenero, D; Tompson, D, 1997
)
0.63
"Based on AUC and Cmax data, it can be concluded that eprosartan has no effect on the pharmacokinetics of a single oral dose of digoxin."( Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers.
Boike, SC; Citerone, D; Ilson, B; Jorkasky, DK; Martin, DE; Tenero, D; Tompson, D, 1997
)
0.88
" After concomitant administration with fluconazole, losartan AUC(0-t) and Cmax were significantly increased 66% and 30%, respectively, compared with those values for losartan alone."( Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
Blum, RA; Boike, SC; Etheredge, R; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Tenero, DM, 1997
)
0.55
" Serial pharmacokinetic samples were obtained for up to 24 hours following eprosartan dosing."( Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
Boike, SC; Boyle, DA; Carr, AM; Ilson, BE; Jorkasky, DK; Lundberg, DE; Martin, DE; Tenero, DM, 1998
)
0.77
" Mean unbound Cmax and AUC0-12 were an average of 53% to 61% and 185% to 210% greater for the patients with moderate and severe renal impairment, respectively, compared with healthy subjects."( Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Boike, SC; Chapelsky, MC; Ilson, B; Jorkasky, DK; Martin, DE; Tenero, D; Zariffa, N, 1998
)
0.57
" There were approximately two fold higher AUC and Cmax values for eprosartan observed in elderly men as compared with young men, most likely due to increased bioavailability of eprosartan in the elderly."( Effect of age and gender on the pharmacokinetics of eprosartan.
Boike, SC; Ilson, B; Jorkasky, DK; Martin, DE; Miller, AK; Tenero, DM; Zariffa, N, 1998
)
0.79
" The drug's terminal elimination half-life is typically 5-9 hours after oral administration."( Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.
Bottorff, MB; Tenero, DM, 1999
)
0.63
" Based on its known safety profile and because of its exaggerated pharmacokinetic variability in patients undergoing hemodialysis, treatment should be individualized based on tolerability and response."( Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
Ilson, BE; Jorkasky, DK; Kovacs, SJ; Martin, DE; Tenero, DM, 1999
)
0.57
" Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compounds are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists."( Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Berellini, G; Cruciani, G; Mannhold, R, 2005
)
0.33
" The following pharmacokinetic parameters were elucidated after administration: the area under the plasma concentration versus time curve from 0 to 32 h (AUC0-32h) 14818."( Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender.
Chen, WL; Chu, NN; Li, XN; Liu, GY; Xu, HR; Yu, C, 2007
)
0.6
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Eprosartan concentration-time profiles were adequately described with a two-compartment pharmacokinetic model with zero-order absorption."( Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients.
Ackaert, O; Koopmans, RP; Mathôt, RA; Ploeger, BA; Snelder, N; van Hest, RM; van Rijn-Bikker, PC, 2013
)
2.06

Compound-Compound Interactions

ExcerptReferenceRelevance
" This article reviews the safety and tolerability of eprosartan in combination with hydrochlorothiazide from 17 studies of 1899 patients with hypertension and normotensive volunteers."( Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Böhm, M; Sachse, A, 2002
)
0.86

Bioavailability

After oral administration of eprosartan to healthy volunteers, bioavailability is approximately 13% with peak plasma concentrations occurring 1-2 hours after an oral dose in the fasted state. There were approximately two fold higher AUC and Cmax values for e Prostartan observed in elderly men as compared with young men.

ExcerptReferenceRelevance
" Oral bioavailability averaged 13."( Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food.
Boike, S; Boyle, D; Ilson, B; Jorkasky, D; Jushchyshyn, J; Lundberg, D; Martin, D; Tenero, D; Zariffa, N, 1998
)
0.54
" There were approximately two fold higher AUC and Cmax values for eprosartan observed in elderly men as compared with young men, most likely due to increased bioavailability of eprosartan in the elderly."( Effect of age and gender on the pharmacokinetics of eprosartan.
Boike, SC; Ilson, B; Jorkasky, DK; Martin, DE; Miller, AK; Tenero, DM; Zariffa, N, 1998
)
0.79
"After oral administration of eprosartan to healthy volunteers, bioavailability is approximately 13%, with peak plasma concentrations occurring 1-2 hours after an oral dose in the fasted state."( Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.
Bottorff, MB; Tenero, DM, 1999
)
0.92
" The effects of eprosartan on RPF are mediated, at least in part, by an increased bioavailability of nitric oxide in the renal vasculature."( Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles, C; Fleischmann, I; Jacobi, J; John, S; Schmieder, RE, 2002
)
0.96
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010
)
0.36
"1-fold increment in oral bioavailability of EM from EMF-O, when compared with plain suspension of pure drug."( Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability.
Dangre, P; Dhole, S; Gilhotra, R, 2016
)
0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Eprosartan (with or without hydrochlorothiazide [HCTZ) demonstrated superior antihypertensive efficacy to that of placebo. When administered at comparable dosage regimens, had similar blood pressure-lowering effects to enalapril. Based on the increase in AUC in patients with hepatic disease compared with those with normal hepatic function, the dosage should be individualized.

ExcerptRelevanceReference
"3 mg/kg) produced dose-dependent parallel shifts in the AII pressor dose-response curve."( Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
Aiyar, N; Edwards, RM; Ezekiel, M; Griffin, E; Keenan, RM; Ohlstein, EH; Ruffolo, RR; Weidley, EF; Weinstock, J, 1992
)
0.28
" Serial blood samples were collected over one dosing interval on study days 10 and 20 for measurement of plasma concentrations of eprosartan, losartan, and E-3174 (the active metabolite of losartan)."( Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers.
Blum, RA; Boike, SC; Etheredge, R; Ilson, B; Jorkasky, DK; Kazierad, DJ; Martin, DE; Tenero, DM, 1997
)
0.76
" Based on the increase in AUC in patients with hepatic disease compared with those with normal hepatic function, the dosage of eprosartan in patients with hepatic disease should be individualized based on tolerability and response."( Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.
Boike, S; Chapelsky, M; Ilson, B; Jorkasky, D; Keogh, J; Martin, D; Patterson, S; Rodriguez, S; Tenero, D,
)
0.56
" Part 1 (n = 12) assessed the onset and duration of the effect of eprosartan 350 mg or placebo; part 2 (n = 14) assessed the dose-response profile of placebo or 10, 30, 50, 70, 100 or 200 mg eprosartan; and part 3 (n = 5) assessed the duration of the effect of 50, 100, or 350 mg eprosartan."( A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Boike, SC; Freed, MI; Ilson, BE; Jorkasky, DK; Martin, DE; Zariffa, N, 1998
)
0.76
" Both dosing regimens provided significant and clinically meaningful reductions in blood pressure that were superior to placebo."( The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
Hedner, T; Himmelmann, A, 1999
)
0.55
" No dosage adjustment is required in patients with mild to moderate renal impairment."( Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations.
Bottorff, MB; Tenero, DM, 1999
)
0.63
" Thus, no dosing adjustments are necessary during concomitant therapy with these agents."( A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.
Blum, RA; Kazierad, DJ; Tenero, DM, 1999
)
0.68
" Whereas a relationship exists between dosage and antihypertensive effect, there is no such relationship between dosage and adverse events, the frequency of which is comparable with that with placebo."( Clinical efficacy of eprosartan.
Weber, M, 1999
)
0.62
" Neither the number nor the severity of these effects increased with prolonged therapy, and their frequency was not affected by increased eprosartan dosage or dosing frequency."( Safety and tolerability of eprosartan.
Gavras, H; Gavras, I, 1999
)
0.8
" Patients received the maximum titrated dosage during the maintenance phase."( Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Argenziano, L; Trimarco, B, 1999
)
0.71
" Patients received the maximum titrated dosage during the maintenance phase."( Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras, H; Gavras, I, 1999
)
0.69
" Patients received the maximum titrated dosage during the maintenance phase."( Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Levine, B, 1999
)
0.71
" Eprosartan 600 mg once daily was both well tolerated and effective, providing significant blood pressure reduction 24 hours after dosing in patients with mild-to-moderate systemic hypertension, regardless of age."( Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman, AH; Gray, J; Maggiacomo, F; Punzi, H; White, WB, 1999
)
1.52
" One such example pertains to the difference in the dose-response relationship for the action of eprosartan on the renal blood supply in comparison with other AT(1) blockers."( Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg, NK, 2001
)
0.78
" To investigate blockade of postsynaptic AT1 receptors, we studied the effect of the AT1 antagonists on dose-response curves elicited by exogenous Ang II."( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001
)
0.51
" Interestingly, the greatest doses of the AT1 antagonists caused less than maximal reduction in the stimulation-induced increase in DBP, resulting in a U-shaped dose-response relationship."( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.
Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001
)
0.51
"These data demonstrate that eprosartan at doses of 600 or 1200 mg significantly reduced BP throughout an entire 24-h dosing period."( Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension.
Anwar, YA; Mansoor, GA; Sica, DA; White, WB, 2001
)
0.86
" Further research is necessary to determine which AT1RBs and which dosing regimens are optimal."( Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Mancini, GB, 2002
)
0.31
" Eprosartan was used in dosage 600 mg daily."( [Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Boĭko, AN; Gusev, EI; Makarov, AN; Martynov, MIu; Petukhov, EB, 2003
)
1.51
"Teveten (eprosartan mesilate) was used as a monotherapy or in combination with hypotiazide (12,5 mg/day) in dosage 600 mg once a day for treatment of 20 patients with cerebrovascular pathology (chronic cerebrovascular insufficiency, consequences of brain ischemica in the presence of arterial hypertension stage I-II, or higher borderline levels of normal blood pressure (BP)."( [Cerebral hemodynamics and endothelium function in patients with cerebrovascular pathology treated by teveten].
foniakin, AV; Geraskina, LA; Konradi, VV; Sharypova, TN; Suslina, ZA, 2005
)
0.75
" The first method, spectrophotometry, was based on the oxidation of this drug by ammonium cerium (IV) nitrate in the presence of perchloric acid with subsequent measurement of the absorbance at 326 nm; this principle was adopted to develop a kinetic method for the determination of eprosartan in dosage forms."( Spectral and polarographic determination of eprosartan. Kinetic studies of the oxidation of eprosartan using a platinum electrode.
El-Yazbi, FA; Hammud, HH; Sonji, GM; Sonji, NM, 2008
)
0.78
" In large, randomized trials, eprosartan (with or without hydrochlorothiazide [HCTZ]) demonstrated superior antihypertensive efficacy to that of placebo and, when administered at comparable dosage regimens, had similar blood pressure-lowering effects to enalapril."( Eprosartan: a review of its use in hypertension.
Plosker, GL, 2009
)
2.08
" Six months ago, the dosage of the drug was doubled, and the patient reported a sudden onset of diarrhea."( Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan.
Hehemann, K; Maier, H; Vieth, M, 2015
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonistA hormone antagonist that blocks angiotensin receptors.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
thiophenesCompounds containing at least one thiophene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Eprosartan Action Pathway74

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)6.65000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.12440.00040.15553.8000AID37697; AID37819
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12440.00040.13343.8000AID37697; AID37819
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)0.12170.00100.39573.3000AID37697; AID39361
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)57.90002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1 angiotensin II receptorHomo sapiens (human)Affinity0.00920.00050.03150.2300AID243379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay IDTitleYearJournalArticle
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37697Inhibition of [125I]AII binding to Angiotensin II receptor, type 1 of rat mesenteric arteries1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID39361In vitro inhibition of [125I]AII specific binding towards Angiotensin II receptor in rat mesenteric membranes.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID182790Dose dependent inhibition of pressor responses to Ang-II in conscious normotensive rat by bolus intravenous administration1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID237841Oral bioavailability2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID182791Dose dependent inhibition of pressor responses to Ang-II receptor in conscious normotensive rat by intraduodenal administration1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1073308Inhibition of HIV1 integrase/LEDGF-75 (unknown origin) interaction2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID568878Inhibition of angiotensin 2-induced response in intraduodenally dosed normotensive rat2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243379Binding affinity for AT1 receptor2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID237099Time required for elimination of 50% of the compound2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID37819Antagonistic activity against [125I]AngII binding to Angiotensin II receptor, type 1 in rat adrenal cortical membrane1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID239885pKa value against human Angiotensin II receptor type 12005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1216814Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID166943Inhibition of angiotensin II induced vasoconstriction of rabbit aorta1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID568877Inhibition of angiotensin 2-induced response in iv dosed normotensive rat2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID236277Volume distribution was determined2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID247113Maximal effect produced by the drug in human2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID182944In vivo inhibition of pressor response to angiotensin II in conscious normotensive rats1993Journal of medicinal chemistry, Jun-25, Volume: 36, Issue:13
Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID183608in vivo inhibition of the pressor response to AII in conscious normotensive rats upon intravenous administration1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID27037Half life of compound was determined2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29138Acid dissociation value was evaluated2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID39652Inhibition against Angiotensin II receptor, type 12003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID39050In vitro inhibition of AII-induced vasoconstriction of rabbit aorta.1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568875Antagonist activity at angiotensin AT1 receptor in rat mesenteric artery membranes2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37820Antagonistic activity against [125I]AngII binding to Angiotensin II receptor, type 1 in rat mesenteric artery1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID27862Total clearance value was evaluated2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID23918Renal clearance value was evaluated2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID320852Antagonist activity at rat AT1 receptor expressed in CHO cells assessed as angiotensin 2-evoked increase in intracellular calcium level2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Selenosartans: novel selenophene analogues of milfasartan and eprosartan.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID568876Antagonist activity at angiotensin AT1 receptor in rat adrenal cortical membranes2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID237981Percentage modification of drug adsorbed after administration to human2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID39791Relative binding affinity of compound to Angiotensin II receptor, type 1 was determined2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346995Human AT1 receptor (Angiotensin receptors)1992The Journal of pharmacology and experimental therapeutics, Jan, Volume: 260, Issue:1
Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (281)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's63 (22.42)18.2507
2000's158 (56.23)29.6817
2010's45 (16.01)24.3611
2020's15 (5.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.76 (24.57)
Research Supply Index5.94 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index86.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials83 (27.95%)5.53%
Reviews49 (16.50%)6.00%
Case Studies5 (1.68%)4.05%
Observational2 (0.67%)0.25%
Other158 (53.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease [NCT01087749]Phase 124 participants (Actual)Interventional2010-03-31Completed
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease [NCT04394117]Phase 4787 participants (Actual)Interventional2020-06-19Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]Phase 42,400 participants (Anticipated)Interventional2016-02-29Recruiting
A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabete [NCT00160160]440 participants Interventional2004-10-31Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]Phase 3341 participants (Actual)Interventional2020-10-09Terminated(stopped due to DSMC recommendation due to futility)
The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System. [NCT00438945]Phase 418 participants (Anticipated)Interventional2007-01-31Completed
The Effect of Eprosartan on Vasoactive Hormones and Renal Tubular Function in Healthy Humans. [NCT00409903]Phase 418 participants (Anticipated)Interventional2006-11-30Completed
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty [NCT04743063]40,000 participants (Anticipated)Observational2021-01-14Active, not recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Losartan and Eprosartan Induce a Similar Effect on Oral Fructose-induced Rise in Serum Uric Acid Concentration in Patients With Metabolic Syndrome [NCT04954560]16 participants (Actual)Interventional2008-01-01Completed
A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension [NCT01631227]Phase 3665 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01631227 (1) [back to overview]Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed Formulation) on Change of Sitting Diastolic Blood Pressure (DBP) From Baseline

Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed Formulation) on Change of Sitting Diastolic Blood Pressure (DBP) From Baseline

Change from baseline of diastolic blood pressure (DBP), sitting (NCT01631227)
Timeframe: 8 weeks

InterventionmmHg (Least Squares Mean)
Eprosartan-7.4
Eprosartan Mesylate-7.2

[back to top]